Another study reported that inhibition of the FAK/PI3K/Akt/mTOR pathway in melanoma cells via subsiding the phosphorylation and activity of major proteins was achieved by the interaction of α1β1/αvβ3 integrin with noncollagenous (NC1) domain of collagen XIX (NC1(XIX)), providing new insight, i.e., anticancer treatments targeting this central signaling pathway in the development of melanoma are promising for the design of new anticancer drugs [47]. The gene discussed is PTK2; the disease is melanoma.